151 related articles for article (PubMed ID: 23956204)
1. Audiologic and vestibular assessment in patients with β-thalassemia major receiving long-term transfusion therapy.
Chao YH; Wu KH; Lin CY; Tsai MH; Peng CT; Wu HP; Lin CD
Pediatr Blood Cancer; 2013 Dec; 60(12):1963-6. PubMed ID: 23956204
[TBL] [Abstract][Full Text] [Related]
2. Audiologic and vestibular assessment in children and adolescents with transfusion dependent beta thalassemia major: The era of deferasirox film coated tablet.
Galhom DH; Talaat RM; Hanna D; Gad NH
Int J Pediatr Otorhinolaryngol; 2024 Feb; 177():111868. PubMed ID: 38252990
[TBL] [Abstract][Full Text] [Related]
3. Long term audiological evaluation of beta-thalassemic patients.
Kontzoglou G; Koussi A; Economou M; Tsatra I; Perifanis V; Noussios G; Athanassiou-Metaxa M
Acta Otorhinolaryngol Belg; 2004; 58(2):113-7. PubMed ID: 15515654
[TBL] [Abstract][Full Text] [Related]
4. Sensorineural hearing loss in β-thalassemia patients treated with iron chelation.
Osma U; Kurtoglu E; Eyigor H; Yilmaz MD; Aygener N
Ear Nose Throat J; 2015 Dec; 94(12):481-5. PubMed ID: 26670754
[TBL] [Abstract][Full Text] [Related]
5. Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload.
Daar S; Pathare AV
Ann Hematol; 2006 May; 85(5):315-9. PubMed ID: 16450126
[TBL] [Abstract][Full Text] [Related]
6. Renal dysfunction in patients with beta-thalassemia major receiving iron chelation therapy either with deferoxamine and deferiprone or with deferasirox.
Economou M; Printza N; Teli A; Tzimouli V; Tsatra I; Papachristou F; Athanassiou-Metaxa M
Acta Haematol; 2010; 123(3):148-52. PubMed ID: 20185899
[TBL] [Abstract][Full Text] [Related]
7. Audiologic and vestibular findings in a sample of human immunodeficiency virus type-1-infected Mexican children under highly active antiretroviral therapy.
Palacios GC; Montalvo MS; Fraire MI; Leon E; Alvarez MT; Solorzano F
Int J Pediatr Otorhinolaryngol; 2008 Nov; 72(11):1671-81. PubMed ID: 18814921
[TBL] [Abstract][Full Text] [Related]
8. Desferrioxamine ototoxicity in an adult transfusion-dependent population.
Chiodo AA; Alberti PW; Sher GD; Francombe WH; Tyler B
J Otolaryngol; 1997 Apr; 26(2):116-22. PubMed ID: 9106087
[TBL] [Abstract][Full Text] [Related]
9. Auditory and visual toxicity during deferoxamine therapy in transfusion-dependent patients.
Chen SH; Liang DC; Lin HC; Cheng SY; Chen LJ; Liu HC
J Pediatr Hematol Oncol; 2005 Dec; 27(12):651-3. PubMed ID: 16344669
[TBL] [Abstract][Full Text] [Related]
10. [Effect of inner ear hearing loss on delayed otoacoustic emissions (TEOAE) and distortion products (DPOAE)].
Hoth S
Laryngorhinootologie; 1996 Dec; 75(12):709-18. PubMed ID: 9081275
[TBL] [Abstract][Full Text] [Related]
11. Sensory neural hearing loss in beta-thalassemia major patients treated with deferoxamine.
Shamsian BS; Aminasnafi A; Moghadassian H; Gachkar L; Arzanian MT; Alavi S; Esfehani H; Garallahi F; Amini R
Pediatr Hematol Oncol; 2008 Sep; 25(6):502-8. PubMed ID: 18728969
[TBL] [Abstract][Full Text] [Related]
12. Audiological evaluation in adult beta-thalassemia major patients under regular chelation treatment.
Ambrosetti U; Dondè E; Piatti G; Cappellini MD
Pharmacol Res; 2000 Nov; 42(5):485-7. PubMed ID: 11023713
[TBL] [Abstract][Full Text] [Related]
13. Improving survival with deferiprone treatment in patients with thalassemia major: a prospective multicenter randomised clinical trial under the auspices of the Italian Society for Thalassemia and Hemoglobinopathies.
Maggio A; Vitrano A; Capra M; Cuccia L; Gagliardotto F; Filosa A; Magnano C; Rizzo M; Caruso V; Gerardi C; Argento C; Campisi S; Cantella F; Commendatore F; D'Ascola DG; Fidone C; Ciancio A; Galati MC; Giuffrida G; Cingari R; Giugno G; Lombardo T; Prossomariti L; Malizia R; Meo A; Roccamo G; Romeo MA; Violi P; Cianciulli P; Rigano P
Blood Cells Mol Dis; 2009; 42(3):247-51. PubMed ID: 19233692
[TBL] [Abstract][Full Text] [Related]
14. Liver fibrosis and iron levels during long-term deferiprone treatment of thalassemia major patients.
Wu SF; Peng CT; Wu KH; Tsai CH
Hemoglobin; 2006; 30(2):215-8. PubMed ID: 16798646
[TBL] [Abstract][Full Text] [Related]
15. Clinically accurate assessment and grading of ototoxicity.
Chang KW
Laryngoscope; 2011 Dec; 121(12):2649-57. PubMed ID: 22109766
[TBL] [Abstract][Full Text] [Related]
16. Predicting the degree of hearing loss using click auditory brainstem response in babies referred from newborn hearing screening.
Baldwin M; Watkin P
Ear Hear; 2013; 34(3):361-9. PubMed ID: 23340456
[TBL] [Abstract][Full Text] [Related]
17. Combined iron chelation therapy.
Galanello R; Agus A; Campus S; Danjou F; Giardina PJ; Grady RW
Ann N Y Acad Sci; 2010 Aug; 1202():79-86. PubMed ID: 20712777
[TBL] [Abstract][Full Text] [Related]
18. Inner ear dysfunction in myotonic dystrophy type 1.
Balatsouras DG; Felekis D; Panas M; Xenellis J; Koutsis G; Kladi A; Korres SG
Acta Neurol Scand; 2013 May; 127(5):337-43. PubMed ID: 23121018
[TBL] [Abstract][Full Text] [Related]
19. A randomized controlled study evaluating the safety and efficacy of deferiprone treatment in thalassemia major patients from Hong Kong.
Ha SY; Chik KW; Ling SC; Lee AC; Luk CW; Lam CW; Ng IO; Chan GC
Hemoglobin; 2006; 30(2):263-74. PubMed ID: 16798652
[TBL] [Abstract][Full Text] [Related]
20. Sequential alternating deferiprone and deferoxamine treatment compared to deferiprone monotherapy: main findings and clinical follow-up of a large multicenter randomized clinical trial in -thalassemia major patients.
Pantalone GR; Maggio A; Vitrano A; Capra M; Cuccia L; Gagliardotto F; Filosa A; Romeo MA; Magnano C; Caruso V; Argento C; Gerardi C; Campisi S; Violi P; Malizia R; Cianciulli P; Rizzo M; D'Ascola DG; Quota A; Prossomariti L; Fidone C; Rigano P; Pepe A; D'Amico G; Morabito A; Gluud C
Hemoglobin; 2011; 35(3):206-16. PubMed ID: 21599433
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
